A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China.
Xiuzhen Zhang(Tongji University), Yuan Jia, Xiaofeng Lu(Chinese Academy of Sciences), Bo Wang(Miami University), Jie Shen(Xinjiang Medical University), Gangyi Yang(Dalian Medical University), Qingyun Xue, Xiaohui Guo(Peking University), Zhimin Liu, Lige Song, Miao Xuan(State Key Laboratory of Applied Organic Chemistry), Jun Yang, Hong Li, Qiu-he Ji, Xiao-Cui Tong, Tianfeng Wu, Cheng-Jiang Li
PubMed
December 20, 2009
Cited by 5
Related Papers
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
<p>Umbilical Cord-Derived Mesenchymal Stem Cell-Derived Exosomes Combined Pluronic F127 Hydrogel Promote Chronic Diabetic Wound Healing and Complete Skin Regeneration</p>
|International Journal of Nanomedicine|2020|521
Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
|Diabetes Care|2012|365
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
The good, the bad, and the ugly of calcium supplementation: a review of calcium intake on human health
|Clinical Interventions in Aging|2018|193